GenNBio Inc. operates in the bio industry in South Korea. It engages in the research and development of xenogeneic organs; conducts non-clinical trial service on primates and rodents; development of artificial organs and new drugs; and is involved in pharmaceutical and medical device distribution business; as well as operates a transplant hospital. The company also offers xenotransplantation process, which is transplanting cells, organs, tissues, etc. from animals to humans. The company was formerly known as KD Nature & Bio CO.,LTD and changed its name to GenNBio Inc. in December 2018. GenNBio Inc. was founded in 1999 and is headquartered in Pyeongtaek-si, South Korea.
Metrics to compare | 072520 | Sector Sector - Average of metrics from a broad group of related Industrials sector companies | Relationship Relationship072520PeersSector | |
---|---|---|---|---|
P/E Ratio | −2.6x | 9.5x | −0.5x | |
PEG Ratio | −0.05 | 0.01 | 0.00 | |
Price/Book | 0.4x | 1.1x | 2.6x | |
Price / LTM Sales | 1,350.8x | 1.9x | 3.0x | |
Upside (Analyst Target) | - | 44.8% | 54.7% | |
Fair Value Upside | Unlock | 16.8% | 8.4% | Unlock |